Thomas Dick

Professor

United States

Research Interests

Explore related searches

Professors in United States Professors in Microbiology Microbiology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Thomas Dick is a faculty member at Hackensack Meridian Health in the United States. His research primarily focuses on mycobacterial infections, including the development of next-generation rifamycins and therapeutic strategies for treating Mycobacterium abscessus lung disease. He has published extensively on the antimicrobial properties of various compounds and their therapeutic applications in tuberculosis and non-tuberculous mycobacterial diseases.

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (5)

Mei Lin Go

National University of Singapore (NUS)

SINGAPORE

View details

mercedes gonzalez-juarrero

Professor

Colorado State University

UNITED STATES

View details

Adrian Richter

Martin Luther University Halle-Wittenberg

GERMANY

View details

Dereje Abate Negatu

Hackensack University Medical Center

UNITED STATES

View details

Volker Müller

Full Professor

Goethe University Frankfurt

GERMANY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Thomas Dick

Research Interests

Explore related searches

Contact this professor

About

Articles (20)

Toward a Bactericidal Oral Drug Combination for the Treatment of Mycobacterium abscessus Lung Disease

Next-generation rifamycins for the treatment of mycobacterial infections.

Preparation of Agar Bead Embedded Mycobacterium abscessus to Inoculate Immunocompetent Mice Intratracheally.

Durlobactam to boost the clinical utility of standard of care β-lactams against Mycobacterium abscessus lung disease

Polymorphism of an Nα-Aroyl-N-Aryl-Phenylalanine Amide: An X-ray and Electron Diffraction Study

Broad-Spectrum In Vitro Activity of Nα-Aroyl-N-Aryl-Phenylalanine Amides against Non-Tuberculous Mycobacteria and Comparative Analysis of RNA Polymerases

Synthesis and in vitro Metabolic Stability of Sterically Shielded Antimycobacterial Phenylalanine Amides

Toward better cures for Mycobacterium abscessus lung disease

Multidrug tolerance conferred by loss-of-function mutations in anti-sigma factor RshA of Mycobacterium abscessus

Therapeutic developments for tuberculosis and nontuberculous mycobacterial lung disease

ADP-ribosylation-resistant rifabutin analogs show improved bactericidal activity against drug-tolerant M. abscessus in caseum surrogate

Blocking ADP-ribosylation expands the anti-mycobacterial spectrum of rifamycins

Characterization of In Vitro Resistance to Linezolid in Mycobacterium abscessus

Side-by-Side Profiling of Oxazolidinones to Estimate the Therapeutic Window against Mycobacterial Infections

PROTAC antibiotics: the time is now

In Vitro Profiling of the Synthetic RNA Polymerase Inhibitor MMV688845 against Mycobacterium abscessus

Redox Cycling Dioxonaphthoimidazoliums Disrupt Iron Homeostasis in Mycobacterium bovis Bacillus Calmette-Guérin

Mycobacterium tuberculosis DprE1 Inhibitor OPC-167832 Is Active against Mycobacterium abscessus In Vitro

Structural Elements Involved in ATP Hydrolysis Inhibition and ATP Synthesis of Tuberculosis and Nontuberculous Mycobacterial F-ATP Synthase Decipher New Targets for Inhibitors

Why Matter Matters: Fast-Tracking Mycobacterium abscessus Drug Discovery

Collaborators (5)

Mei Lin Go

mercedes gonzalez-juarrero

Adrian Richter

Dereje Abate Negatu

Volker Müller

Make your next move.